Cinnarizine as an alternative recommendation for migraine prophylaxis: a narrative review

References

• Dodick DW. Migraine. Lancet. 2018;391(10127):1315–1330.
   PubMed Web of Science ®Google Scholar
• ABU‐ARAFEH I, RAZAK S, SIVARAMAN B, et al. Prevalence of headache and migraine in children and adolescents: A systematic review of population‐based studies. Dev Med Child Neurol. 2010;52(12):1088–1097.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267(1):64–69.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–657.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349.
   PubMed Web of Science ®Google Scholar
• Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631–649.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Akerman S, Goadsby PJ. Efficacy and mechanism of anticonvulsant drugs in migraine. Expert Rev Clin Pharmacol. 2014;7(2):191–201.
   PubMed Web of Science ®Google Scholar
• Gelmers HJ. Calcium-channel blockers in the treatment of migraine. Am J Cardiol. 1985;55(3):139b–143b.
   PubMed Web of Science ®Google Scholar
• Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol. 1969;21(3):263–268.
   PubMed Web of Science ®Google Scholar
• Banzi R, Cusi C, Randazzo C, et al. Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev. 2015;(4).
   Web of Science ®Google Scholar
• Burch R. Antidepressants for Preventive Treatment of Migraine. Curr Treat Options Neurol. 2019;21(4):18.
   PubMed Web of Science ®Google Scholar
• Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One. 2019;14(3):e0212785.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338.
   PubMed Web of Science ®Google Scholar
• Society AH. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.
   Web of Science ®Google Scholar
• Oskoui M, Pringsheim T, Billinghurst L, et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2019;93(11):500–509.
   PubMed Web of Science ®Google Scholar
• Arab SF, Düwel P, Jüngling E, et al. Inhibition of voltage-gated calcium currents in type II vestibular hair cells by cinnarizine. Naunyn-Schmiedeberg’s Arch Pharmacol. 2004;369(6):570–575.
   Google Scholar
• Haress NG. Cinnarizine: comprehensive Profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:1–41.
   PubMedGoogle Scholar
• Headache, I.S.f.t.S.o. Guidelines and recommendations for the treatment of migraine. Funct Neurol. 1993;8(6):441–446.
   PubMedGoogle Scholar
• Amanat M, Togha M, Agah E, et al. Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial. Cephalalgia. 2019;40(7):665–674 .0333102419888485.•• A well design and relatively large study regarding the cinnarizine effects on pediatrics migraine prophylaxis
   Google Scholar
• Togha M, Malamiri RA, Rashidi-Ranjbar N, et al. Efficacy and safety of cinnarizine in the prophylaxis of migraine headaches in children: an open, randomized comparative trial with propranolol. Acta Neurol Belg. 2012;112(1):51–55.
   PubMed Web of Science ®Google Scholar
• Ashrafi MR, Najafi Z, Shafiei M, et al. Cinnarizine versus topiramate in prophylaxis of migraines among children and adolescents: a randomized, double-blind clinical trial. Iran J Child Neurol. 2014;8(4):18.
   PubMedGoogle Scholar
• Mansoureh T, Rahmat Jirde M, Nilavari K, et al. Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate. J Headache Pain. 2008;9(2):77.
   PubMed Web of Science ®Google Scholar
• Bostani A, Rajabi A, Moradian N, et al. The effects of cinnarizine versus sodium valproate in migraine prophylaxis. Int J Neurosci. 2013;123(7):487–493.
   PubMed Web of Science ®Google Scholar
• Taghdiri F, Togha M, Razeghi Jahromi S, et al. Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study. SpringerPlus. 2014;3(1):231.
   PubMedGoogle Scholar
• Ashrafi MR, Salehi S, Malamiri RA, et al. Efficacy and safety of cinnarizine in the prophylaxis of migraine in children: a double-blind placebo-controlled randomized trial. Pediatr Neurol. 2014;51(4):503–508.
   PubMed Web of Science ®Google Scholar
• Togha M, Ashrafian H, Tajik P. Open-label trial of cinnarizine in migraine prophylaxis. Headache. 2006;46(3):498–502.
   PubMed Web of Science ®Google Scholar
• Rossi P, Fiermonte G, Pierelli F. Cinnarizine in migraine prophylaxis: efficacy, tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial.. Funct Neurol. 2003;18(3):155–160.
   PubMed Web of Science ®Google Scholar
• Raghuvanshi S, Pathak K. Recent advances in delivery systems and therapeutics of cinnarizine: a poorly water soluble drug with absorption window in stomach. J Drug Deliv. 2014;2014:479246.
   PubMedGoogle Scholar
• Teive HAG, Troiano AR, Germiniani FMB, et al. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord. 2004;10(4):243–245.
   PubMed Web of Science ®Google Scholar
• Negrotti A, Calzetti S. A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonism. Mov Disord. 1997;12(1):107–110.
   PubMed Web of Science ®Google Scholar
• Martí‐Massó JF, Poza JJ. Cinnarizine‐induced parkinsonism: ten years later. Mov Disord. 1998;13(3):453–456.
   PubMed Web of Science ®Google Scholar
• Kelman L. Migraine changes with age: IMPACT on migraine classification. Headache. 2006;46(7):1161–1171.
   PubMed Web of Science ®Google Scholar
• Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med. 1996;334(2):71–76.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goadsby PJ, Sawyer JP, et al. Migraine: diagnosis and assessment of disability. Rev Contemp Pharmacother. 2000;11(2):63–73.
   Web of Science ®Google Scholar
• Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe–evidence from the Eurolight study. J Headache Pain. 2018;19(1):10.
   PubMedGoogle Scholar
• Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain. 2017;18(1):96.
   PubMed Web of Science ®Google Scholar
• Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache. 2003;43(1):36–43.
   PubMed Web of Science ®Google Scholar
• Byun YJ, Levy DA, Nguyen SA, et al. Treatment of vestibular migraine: a systematic review and meta-analysis. Laryngoscope. 2020. DOI:10.1002/lary.28546.
   PubMed Web of Science ®Google Scholar
• Freitag F, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58(11):1652–1659.
   PubMed Web of Science ®Google Scholar
• Zawab A, Carmody J. Safe use of sodium valproate. Australian Prescriber. 2014,37 (4):124–127 doi:10.18773/austprescr.2014.048
   Google Scholar
• Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323–1338.
   PubMed Web of Science ®Google Scholar
• O’Brien HL, Cohen JM. Young adults with headaches: the transition from adolescents to adults. Headache. 2015;55(10):1404–1409.
   PubMed Web of Science ®Google Scholar
• Le K, Yu D, Wang J, et al. Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials. J Headache Pain. 2017;18(1):69.
   PubMedGoogle Scholar
• Pianese CP, Hidalgo LOV, González RH, et al. New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study. Otol Neurotol. 2002;23(3):357–363.
   PubMed Web of Science ®Google Scholar
• Hausler R, Sabani E, Rohr M. Effect of cinnarizine on various types of vertigo. Clinical and electronystagmographic results of a double-blind study. Acta oto-rhino-laryngologica Belgica. 1989;43(2):177–185.
   PubMedGoogle Scholar
• Scholtz A-W, Steindl R, Burchardi N, et al. Comparison of the Therapeutic efficacy of a fixed low-dose combination of cinnarizine and Dimenhydrinate with Betahistine in vestibular neuritis. Clin Drug Investig. 2012;32(6):387–399.
   PubMed Web of Science ®Google Scholar